TY - JOUR
T1 - Donor lymphocyte infusions in adolescents and young adults for control of advanced pediatric sarcoma
AU - Schober, Sebastian J.
AU - von Luettichau, Irene
AU - Wawer, Angela
AU - Steinhauser, Maximilian
AU - Salat, Christoph
AU - Schwinger, Wolfgang
AU - Ussowicz, Marek
AU - Antunovic, Petar
AU - Castagna, Luca
AU - Kolb, Hans Jochem
AU - Burdach, Stefan E.G.
AU - Thiel, Uwe
N1 - Publisher Copyright:
© Schober et al.
PY - 2018/4/27
Y1 - 2018/4/27
N2 - Background: Allogeneic stem cell transplantation (allo-SCT) and donor lymphocyte infusions (DLI) may induce a graft-versus-tumor effect in pediatric sarcoma patients. Here, we describe general feasibility, toxicity and efficacy of DLI after allo-SCT. Results: 4 of 8 patients responded. ES#4 had stable disease (SD) for 9 months after DLI and RMS#4 partial response for 8 months with combined hyperthermia/ chemotherapy. In ES#4, DLI led to SD for 6 months and reverted residual disease before allo-SCT into complete remission. After DLI, ES#4 and RMS#4 developed acute GvHD (°III-°IV), ES#4 also developed chronic GvHD. 5 patients including ES#4 lived longer than expected. Median survival after allo-SCT was 2.3 years, post-relapse survival (PRS) was 13 months. Off note, HLA-mismatched DLI were associated with a trend towards increased survival after allo-SCT and increased PRS compared to HLA-matched DLI (23 versus 3 months). Materials and Methods: We studied eight adolescents and young adults (AYAs) with advanced Ewing sarcoma (ES#1-4) and rhabdomyosarcoma (RMS#1-4) who received DLI. Escalating doses ranged from 2.5 x 104 to 1 x 108 CD3+ cells/kg body weight. AYAs were evaluated for response to DLI, graft-versus-host disease (GvHD) and survival. Conclusions: DLI after allo-SCT may control advanced pediatric sarcoma in AYAs with controllable toxicity.
AB - Background: Allogeneic stem cell transplantation (allo-SCT) and donor lymphocyte infusions (DLI) may induce a graft-versus-tumor effect in pediatric sarcoma patients. Here, we describe general feasibility, toxicity and efficacy of DLI after allo-SCT. Results: 4 of 8 patients responded. ES#4 had stable disease (SD) for 9 months after DLI and RMS#4 partial response for 8 months with combined hyperthermia/ chemotherapy. In ES#4, DLI led to SD for 6 months and reverted residual disease before allo-SCT into complete remission. After DLI, ES#4 and RMS#4 developed acute GvHD (°III-°IV), ES#4 also developed chronic GvHD. 5 patients including ES#4 lived longer than expected. Median survival after allo-SCT was 2.3 years, post-relapse survival (PRS) was 13 months. Off note, HLA-mismatched DLI were associated with a trend towards increased survival after allo-SCT and increased PRS compared to HLA-matched DLI (23 versus 3 months). Materials and Methods: We studied eight adolescents and young adults (AYAs) with advanced Ewing sarcoma (ES#1-4) and rhabdomyosarcoma (RMS#1-4) who received DLI. Escalating doses ranged from 2.5 x 104 to 1 x 108 CD3+ cells/kg body weight. AYAs were evaluated for response to DLI, graft-versus-host disease (GvHD) and survival. Conclusions: DLI after allo-SCT may control advanced pediatric sarcoma in AYAs with controllable toxicity.
KW - Allogeneic stem cell transplantation
KW - Alloimmunity and transplantation
KW - Donor lymphocyte infusion
KW - Ewing sarcoma
KW - Rhabdomyosarcoma
UR - http://www.scopus.com/inward/record.url?scp=85046103063&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.25228
DO - 10.18632/oncotarget.25228
M3 - Article
AN - SCOPUS:85046103063
SN - 1949-2553
VL - 9
SP - 22741
EP - 22748
JO - Oncotarget
JF - Oncotarget
IS - 32
ER -